Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 3, 2005

View Archived Issues

Eisai licenses E-6020 vaccine adjuvant to Sanofi Pasteur

Nexavar selected as trade name for sorafenib

Ark Therapeutics announces preliminary results from study of Vitor in cachexia

Tibotec opens U.S. expanded access program for TMC-114

Radilex reduces formalin-induced lung injury

Enrollment discontinued in phase III study of Reopro for acute ischemic stroke

Private financing to fund pipeline progression at Surface Logix

Novartis to acquire remaining shares in Chiron

Protocol accepted for phase IIb MS trial of Tovaxin

Encouraging findings from study of Chiron's adjuvanted avian flu vaccine

Bristol-Myers Squibb profiles Q3 developments

Antibody-derived GLYX-13 possesses cognitive-enhancing properties

Orphan drug designation for ZD-6474 for thyroid cancers

Soltamox receives FDA approval

Rituxan sBLA for rheumatoid arthritis granted priority review

Recent Aventis patent claims novel therapeutic agents for thrombotic disorders

Novel treatment options for cardiovascular disorders disclosed in recent patents

D3 receptors validated as a target in gastric motility disorders

Novel therapeutics for genitourinary disorders claimed in recent Roche patent

Analgesic agents revealed in recent patents

First worldwide approval for Exjade in U.S.

Tarceva approved in combination with gemcitabine for pancreatic cancer

Pimozide shows promise in the treatment of uncontrollable eructation

Studies support the use of INKP-102 as a novel purgative before colonoscopy

Update on lubiprostone in the management of constipation

Novel microsomal triglyceride transfer protein inhibitor, SLx-4090, identified

Phase III data on SPD-476 in ulcerative colitis presented at gastroenterology meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...